Bafetinib Suppresses the Transcription of PD-L1 Through c-Myc in Lung Cancer
Given the limitations of the existing antibody-based therapies, including immune-related adverse events, poor response rates, and intravenous route of dosing, small molecules inhibitors targeting PD-L1 are highly desirable. By cell-based screening, we found that tyrosine kinase inhibitor Bafetinib d...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2022-06-01
|
| coleção: | Frontiers in Pharmacology |
| Assuntos: | |
| Acesso em linha: | https://www.frontiersin.org/articles/10.3389/fphar.2022.897747/full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|